Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis, Inc., (OTCBB: ADXS) ("Advaxis" or the "Company"), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG).

“This milestone marks the beginning of the development of ADXS-HPV in diseases beyond cervical cancer. It also will provide valuable insight into the combination of ADXS-HPV with concurrent radiation and chemotherapy”

This study will expand the clinical investigation of ADXS-HPV to now a third tumor type, following cervical cancer and head and neck cancer.

This non-randomized, open-label, multi-center study will evaluate the safety and effectiveness of ADXS-HPV when combined with standard chemotherapy and radiation treatment for anal cancer. The primary objectives of the trial include the evaluation of adverse events and the evaluation of 6-month clinical response.

"This milestone marks the beginning of the development of ADXS-HPV in diseases beyond cervical cancer. It also will provide valuable insight into the combination of ADXS-HPV with concurrent radiation and chemotherapy," commented Dr. Robert Petit, VP of Clinical Operations and Medical Affairs at Advaxis.